Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cord blood allogeneic HSCT with TFACT conditioning
ChiCTR2500108003Phase 4Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Aug 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of thiotepa, fludarabine, cytarabine and cyclophosphamide in leukemia, bone marrow failure, myelodysplastic syndrome (MDS) and 1 more, sponsored by Hangzhou First People's Hospital. Primary endpoint: Overall survival at day 100 after transplantation. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
thiotepafludarabinecytarabinecyclophosphamide
03
Conditions
leukemiabone marrow failuremyelodysplastic syndrome (MDS)lymphoma
Beyond the preview
Go deeper on ChiCTR2500108003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108003.